Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 23;15(5):1313–1322. doi: 10.1111/ajt.13111

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. American Journal of Transplantation Published by The American Society of Transplantation and the American Society of Transplant Surgeons

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Simulated concentration‐time profile for coadministration of tacrolimus 0.5 mg every 7 days with the 3D regimen. QD, once daily; BID, twice daily. Note: The plot illustrates the timeline from the time a patient undergoes transplant through the first 2 weeks of 3D (ABT‐450/ritonavir 150/100 mg once daily, ombitasvir 25 mg once daily, and dasabuvir 400 mg twice daily) treatment. The mean concentration‐time profile for tacrolimus is shown (black and blue lines). The grey lines illustrate the tacrolimus profile in the absence of 3D treatment. Subjects were assumed to have a stable tacrolimus C_trough of 5 ng/mL when initiating 3D treatment. Further modifications in tacrolimus dose or dosing frequency should be guided by trough levels measured during coadministration with the 3D regimen.